A multicenter trial of oxcarbazepine oral suspension monotherapy in children newly diagnosed with partial seizures: A clinical and cognitive evaluation

So Hee Eun, Heung Dong Kim, Hee Jung Chung, Hoon Chul Kang, Joon Soo Lee, Joon Sik Kim, Su Jeong You, Han Ku Moon, Young Mock Lee, Dong Wook Kim, Eun Sook Suh, Ji Yeon Kim, Juneyoung Lee, Baik Lin Eun

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose: We conducted a prospective, multicenter, open label trial to evaluate the effectiveness of oxcarbazepine (OXC) oral suspension as monotherapy for children newly diagnosed with partial seizures. Methods: This trial included a two- to eight-week titration and stabilization period to achieve effective target doses and a 24-week maintenance phase. The primary outcome measure was the seizure-free rate over six months, while a secondary measure was the change in cognition and behavior from screening to the end of the maintenance phase. The effectiveness of OXC was compared in intellectually normal versus intellectually impaired children (intelligence quotient <70). Results: We enrolled 171 patients and analyzed 168 as the per-protocol (PP) group (3 patients had protocol violations). The mean age of the PP group was 8.4 ± 2.7 years. The maintenance dose of OXC was 24.9 ± 8.0 mg/kg/day. Of the 168 patients included in the efficacy analysis, 122 (72.6%) completed the study and 94 (56.0%) became seizure-free after the OXC treatment. Comparing the efficacy of OXC for intellectually normal and intellectually impaired patients, 79 (56.8%) of the 139 intellectually normal patients and 15 (51.7%) of the 29 intellectually impaired patients became seizure-free (P = 0.61). After treatment, intelligence scale scores improved in intellectually normal patients compared to the intellectually impaired children (P < 0.05). Social problems quantified by behavior scales improved in intellectually impaired patients compared to intellectually normal children (P < 0.05). Conclusions: OXC is effective and well-tolerated as monotherapy in children with partial seizures. There was no difference in the effectiveness of OXC between intellectually normal and intellectually impaired children.

Original languageEnglish
Pages (from-to)679-684
Number of pages6
JournalSeizure
Volume21
Issue number9
DOIs
Publication statusPublished - 2012 Nov 1

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Cite this

Eun, S. H., Kim, H. D., Chung, H. J., Kang, H. C., Lee, J. S., Kim, J. S., You, S. J., Moon, H. K., Lee, Y. M., Kim, D. W., Suh, E. S., Kim, J. Y., Lee, J., & Eun, B. L. (2012). A multicenter trial of oxcarbazepine oral suspension monotherapy in children newly diagnosed with partial seizures: A clinical and cognitive evaluation. Seizure, 21(9), 679-684. https://doi.org/10.1016/j.seizure.2012.07.007